BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate ...

ProPhase Labs emphasizes its commitment to innovative healthcare solutions and aims to leverage its advisory board's expertise for the widespread adoption of BE-Smart in clinical practice.

November Company Presentation ProPhase Labs, Inc. stock currently trades just above seven bucks a share and has an approximate market capitalization of $125 million. Third Quarter Results: ...

ProPhase Labs, Inc. 267-880-1111 investorrelations@prophaselabs.com Retail Investor Relations Contact: Renmark Financial CommunicationsJohn Boidman 514-939-3989 Jboidman@renmarkfinancial.com ...